Abstract
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by MSK-IMPACT. RB1 and TP53 status was determined based on integrated genomic and IHC data (see “Results”). B, Tabular and (C) pictorial summary of pathologic sample characteristics and sequencing assays performed for 20 patients with aSCLC. See “Methods” for histopathologic criteria. Ki67 not available. D, Summary of metastatic site distribution based on radiologic–pathologic findings (full data in Supplementary Table S2). E–G, Compilation of radiologic and pathologic findings for three representative patients. E, (A01): 19-year-old patient with brain metastasis showing classic undifferentiated morphology of SCLC: small, crowded/molding cells, numerous mitotic figures (>50/2 mm2), apoptotic bodies, and Ki67 of 90%, whereas thoracic sample shows well-differentiated, nested morphology of a carcinoid tumor lacking mitotic figures or apoptotic bodies, and exhibiting Ki67 of 5%–20%. F, Case A08 and (G) case A09 illustrate classic SCLC morphology in primary lung tumor samples, featuring Ki67 rate of 80% and 90%, respectively. n indicates areas of extensive necrosis–a hallmark feature of SCLC. For extended pathologic illustrations, see Supplementary Figs. S1–S4. Scale bars are 100 μm for Ki67 and 50 μm for H&E except for top in F which is 1 mm. H, Comparison of age, Ki67 proliferation index, and smoking pack-years in aSCLC vs. other SCLC (n = 224 for age and Ki67; n = 200 for pack-year smoking). For patients with multiple samples, Ki67 represents the maximal (max) hot-spot rate among all evaluated samples. H&E, hematoxylin and eosin; FNA, fine needle aspiration; Core bx, core biopsy; py, pack-years; tNGS, targeted next-generation sequencing. (C, D created in part with BioRender.com.)